Table 2.

Development of Acute TB in Cancer Patients Treated With ICIs.

Reference	Age/sex	Tumor type	ICI
van Eeden et al 55	56 Y/female	NSCLC	Nivolumab
Inthasot et al 56	69 Y/male	NSCLC	Nivolumab
	57 Y/female	NSCLC	Nivolumab
Barber et al 57	59 Y/male	NPC	Nivolumab
	83 Y/male	MCC	Pembrolizumab
Anastasopoulou et al 58	76 Y/female	Melanoma	Nivolumab
	85 Y/male	Melanoma	Atezolizumab
Jensen et al 59	56 Y/male	NSCLC	Nivolumab
Chu et al 60	59 Y/male	NSCLC	Nivolumab
Fujita et al 61	72 Y/male	NSCLC	Nivolumab
Picchi et al 62	65 Y/female	Melanoma	Pembrolizumab
Lee et al 63	87 Y/male	HL	Pembrolizumab
He et al 64	65 Y/female	Melanoma	Pembrolizumab
Elkington et al 65	62 Y/female	Ocular melanoma	Ipilimumab

Abbreviations: HL, Hodgkin’s lymphoma; ICIs, Immune checkpoint inhibitors; MCC, Merkel cell carcinoma; NSCLC, Non-small cell lung cancer; NPC, nasopharyngeal carcinoma; TB, Tuberculosis.